Clearwater Paper (CLW) Q4 2023 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2023 earnings summary
31 Oct, 2026Executive summary
FY 2023 net sales were $2,082.8M and net income was $107.7M; Adjusted EBITDA was $281.0M, up $54.1M YoY.
Consumer Products gains offset soft demand, lower pricing and reduced operating rates in Pulp and Paperboard.
Strategic priorities include paperboard growth through the pending Augusta acquisition and exploring strategic options for the tissue business.
Financial highlights
Q4 net sales were $512.8M versus $526.7M in Q4 2022; FY net sales were $2,082.8M versus $2,080.1M.
Q4 net income was $17.6M versus a $5.9M loss; FY net income was $107.7M versus $46.0M.
Adjusted net income was $22.8M in Q4 and $114.4M for FY 2023; Adjusted EBITDA was $63.3M and $281.0M, respectively.
FY operating income was $177.1M versus $113.9M; diluted EPS was $6.30 versus $2.68, and adjusted diluted EPS was $6.69 versus $3.63.
Outlook and guidance
Q1 2024 Adjusted EBITDA guidance is $53M–$63M, including a weather-related impact at Lewiston; paperboard demand and production volumes are expected to increase, with continued strong tissue performance.
FY 2024 assumptions include a $15M–$25M positive volume impact, $30M–$35M negative major-maintenance impact at Lewiston, and $40M–$50M negative price/cost impact.
FY 2024 assumptions include interest expense of $28M–$30M, D&A of $97M–$100M, capex of $90M–$100M and an effective tax rate of ~25%–26%; assumptions exclude Augusta.
Outlook anticipates continued tissue strength and a paperboard demand recovery in H2 2024; Augusta was expected to close in Q2, subject to approvals and customary conditions.
Latest events from Clearwater Paper
- Q3 Adjusted EBITDA rose to $24.4 million, but Augusta disruptions weigh on Q4.CLW
Q3 2026 - Q2 2026 net loss on lower prices despite volume growth; cost cuts and debt reduction aided liquidity.CLW
Q2 2026 - Net sales fell 5% as lower pricing and higher costs drove a net loss despite volume growth.CLW
Q1 2026 - 2025 saw strong sales growth, cost savings, and major governance and ESG initiatives up for shareholder vote.CLW
Proxy filing - Board recommends approval of all director nominees, auditor, compensation, and governance changes.CLW
Proxy filing - Major transformation, cost savings, and ESG progress drive 2026 proxy proposals and governance.CLW
Proxy Filing - Net sales up 12%, Adjusted EBITDA at $107M, but goodwill impairment drove a net loss.CLW
Q4 2025 - Q2 net sales up 12% but net loss; tissue sale to reduce debt and boost paperboard focus.CLW
Q2 2024 - Augusta mill acquisition boosts scale and reach as high utilization supports strong margins.CLW
Stifel 2024 Cross Sector Insight Conference